Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now

Brazilian lawmaker denouncing vaccine deal wears bullet-proof vest to hearing

Published Jun 25, 2021 05:55PM ET Updated Jun 25, 2021 09:56PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
5/5 © Reuters. Brazilian Federal Deputy Luis Miranda walks before a meeting of the Parliamentary Inquiry Committee (CPI) to investigate government actions and management during the coronavirus disease (COVID-19) pandemic, at the Federal Senate in Brasilia, Brazil June 2 2/5
 
PFE
-0.23%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Maria Carolina Marcello

BRASILIA (Reuters) -A Brazilian congressman who has denounced alleged wrongdoing in a 1.6 billion reais ($323 million) COVID-19 vaccine contract signed by Brazil's government arrived at a Senate commission inquiry on Friday wearing a bullet-proof vest for safety.

Congressman Luis Miranda and his brother Luis Ricardo Miranda, the whistleblower at the Health Ministry who raised suspicions about the vaccine deal with India's Bharat Biotech, are the key witnesses in a hearing underway on Friday.

The parliamentary inquiry is looking into the government's handling of the coronavirus pandemic that has killed more than half a million people in Brazil, and accusations that it deliberately delayed securing vaccines to fight COVID-19.

Far-right President Jair Bolsonaro, who is under growing pressure to explain the deal with Bharat, said on Friday there were no irregularities in the contract for the Indian drugmaker's Covaxin shot.

"There is nothing wrong with the Covaxin contract, there is no overpricing," he said at a news conference in the interior of São Paulo.

The president, who was elected on an anti-graft platform, added that his enemies were trying to stain his government with unfounded accusations of corruption.

"I am incorruptible," he said.

The allegations regarding the Bharat contract threaten to damage Bolsonaro's pledge of zero tolerance for corruption in his government.

The coordinator of the Senate inquiry has called for protection for the Miranda brothers, and also for the owners of the Brazilian company Precisa Medicamentos, which acts as an intermediary for Bharat.

The contract is being probed by federal prosecutors and lawmakers to see why the government struck a speedy agreement with Bharat after COVID-19 vaccine offers from Pfizer Inc (NYSE:PFE) at a lower price were ignored.

Luis Ricardo Miranda and his lawmaker brother met with Bolsonaro in March and said they warned him of the suspicious contract, but that nothing was done to investigate the deal.

Legislator Luis Miranda said that Bolsonaro recognized that the situation was serious and told them that another congressman, Ricardo Barros, was involved in the Bharat deal.

Barros, the government's whip in the legislature's lower house, responded on Twitter that he had no involvement in the Bharat deal and that further investigation would show the president did not cite his name in the meeting.

Bolsonaro's press office did not immediately respond to a request for comment about implicating Barros.

Luis Ricardo Miranda, head of imports at the Health Ministry, told senators he refused to approve an import license because an invoice for a first shipment asked for up-front payment and was sent by a company not mentioned in the contract, Singapore-based Madison Biotech.

Miranda has told prosecutors he was pressured by Alex Lial Marinho, an aide to one of Bolsonaro's closest allies, former Health Minister Eduardo Pazuello. Miranda's account was backed up by his congressman brother.

The accusations raise awkward questions for Bolsonaro and Pazuello, who is facing criminal and civil investigations into his handling of the pandemic while minister.

On Thursday, Bolsonaro said Brazil never paid for or received any doses of the Covaxin shot, and pledged to take action if any corruption was discovered in his government.

In a statement issued in India, Bharat Biotech said, "We strongly refute and deny any kind of allegation or implication of any wrongdoing whatsoever with respect to the supply of COVAXIN." It said Madison Biotech was its global sales and marketing unit.

($1 = 4.9477 reais)

Brazilian lawmaker denouncing vaccine deal wears bullet-proof vest to hearing
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email